HealthCare Global Enterprises Limited (NSE:HCG)
India
· Delayed Price · Currency is INR | Market Cap | 86.15B |
| Revenue (ttm) | 24.78B |
| Net Income (ttm) | 189.50M |
| Shares Out | 149.30M |
| EPS (ttm) | 1.34 |
| PE Ratio | 454.64 |
| Forward PE | 71.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,732 |
| Average Volume | 204,097 |
| Open | 580.35 |
| Previous Close | 577.45 |
| Day's Range | 571.50 - 583.95 |
| 52-Week Range | 513.30 - 804.65 |
| Beta | -0.24 |
| RSI | 58.10 |
| Earnings Date | May 26, 2026 |
About NSE:HCG
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, ... [Read more]
Financial Performance
In fiscal year 2025, NSE:HCG's revenue was 22.23 billion, an increase of 16.25% compared to the previous year's 19.12 billion. Earnings were 444.10 million, a decrease of -7.78%.
Financial StatementsNews
HCG shares fall 2% after board approves Rs 424 crore rights issue at Rs 512 per share
Shares of Healthcare Global Enterprises (HCG) declined 1.95% to Rs 573.30 in early trade on February 25 after the company...
HealthCare Global Enterprises Ltd (NSE:HCG) Q3 2026 Earnings Call Highlights: Strong Revenue ...
HealthCare Global Enterprises Ltd (NSE:HCG) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion Plans
Q3 2026 Healthcare Global Enterprises Ltd Earnings Call Transcript
Q3 2026 Healthcare Global Enterprises Ltd Earnings Call Transcript
HealthCare Global Enterprises Transcript: Q3 25/26
Q3 revenue grew 13.4% year-over-year to INR 633 crore, with adjusted EBITDA up 20% and margins expanding. Guidance remains at 15%+ annual growth, with margin and ROCE expected to rise as centers mature and new expansions come online.
HealthCare Global Enterprises Transcript: Q4 24/25
Strong revenue and EBITDA growth in FY 2025 was driven by core oncology centers, expansion, and digital initiatives. Margin improvement is expected as emerging centers mature, with over 900 new beds planned in three years and a focus on reducing debt through equity infusion.
HCG Aastha Cancer Centre expands operations in Ahmedabad with state’s largest private oncology facility
Ahmedabad, April 19, 2025 — HealthCare Global Enterprises Ltd (HCG) has officially inaugurated the expanded HCG Aastha Cancer Centre in Ahmedabad, Gujarat. The new facility, located opposite Bhagwat V...
Q3 2025 Healthcare Global Enterprises Ltd Earnings Call Transcript
Q3 2025 Healthcare Global Enterprises Ltd Earnings Call Transcript
KKR & Co Inc (KKR) Acquires Majority Stake in Healthcare Global Enterprises
KKR & Co Inc (KKR) Acquires Majority Stake in Healthcare Global Enterprises
Healthcare Global stock jump 3.2% after KKR announces 54% stake acquisition for $400 million
Healthcare Global Enterprises (HCG) stock jumped 5% after global investment firm KKR announced the acquisition of a controlling stake in the oncology hospital chain for $400 million. As of 9:17 AM, th...
KKR to buy 51% in oncology hospital HealthCare Global
American private equity fund KKR will acquire a 51% stake in HealthCare Global Enterprises for Rs 3,203 crore, making an open offer for an additional 26% stake. Founder B S Ajaikumar will become non-e...
KKR acquires 54% stake in in Healthcare Global Enterprises for Rs 3,468 crore
KKR has announced the acquisition of a controlling stake in Healthcare Global Enterprises (HCG) for $400 million, marking a significant move in India’s healthcare sector. As part of the agreement, KKR...
HealthCare Global Enterprises Transcript: Q3 24/25
Q3 FY25 saw record revenue of INR 559 crore (+19% YoY) and strong EBITDA growth, with emerging centers and recent acquisitions driving performance. KKR's majority stake marks a strategic shift, while margin expansion and robust growth are expected in the coming quarters.
HealthCare Global Enterprises Ltd (NSE:HCG) Q2 FY25 Earnings Call Highlights: Robust Revenue ...
HealthCare Global Enterprises Ltd (NSE:HCG) Q2 FY25 Earnings Call Highlights: Robust Revenue Growth and Strategic Digital Expansion
Q2 2025 Healthcare Global Enterprises Ltd Earnings Call Transcript
Q2 2025 Healthcare Global Enterprises Ltd Earnings Call Transcript
HealthCare Global Enterprises Earnings Call Transcript: Q2 2025
Q2 FY25 saw record revenue and EBITDA growth, with margins expanding and digital initiatives driving patient acquisition. Expansion through acquisitions and new centers continues, while international business is expected to recover by Q4.
Healthcare Global Enterprises Q2 FY25 Results: Revenue at ₹552.47 Crore, Up 13.9% YoY; Profit at ₹20.68 Crore, Up 91.7% YoY
Healthcare Global Enterprises Ltd. reported its consolidated financial results for the second quarter of FY25, showing robust growth in both revenue and profit compared to the same quarter last year. ...
Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus
Key stocks to watch include Ashoka Buildcon, CESC, SMS Pharmaceuticals, PVR INOX, HealthCare Global Enterprises, Zydus Lifesciences, Reliance Power, Reliance Infra, Vikas Lifecare, Eraaya Lifespaces, ...
HealthCare Global Enterprises completes acquisition of 51% stake in Vizag Hospital
HealthCare Global Enterprises Limited (HCG), a leading cancer care provider, has announced the completion of its acquisition of a 51% equity stake in Vizag Hospital and Cancer Research Centre Private ...
Bain Is Said to Be Frontrunner For Indian Hospital Chain HCG
Bain Capital has emerged as the frontrunner to acquire a controlling stake in Indian cancer hospital chain HealthCare Global Enterprises Ltd., according to people familiar with the matter.
HealthCare Global Enterprises Earnings Call Transcript: Q1 2025
Q1 FY25 saw record revenue and EBITDA growth, driven by strong performance across centers, strategic acquisition in Vizag, and digital initiatives. EBITDA margin is expected to reach 19%-20% for established centers, with continued investment in expansion and operational efficiency.